Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in locally advanced esophageal squamous cell carcinoma
NCT04084158Phase 2Suspended
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Started Sep 2019; status: suspended.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04084158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084158.